Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 4, 2005, Pages 333-342

  Fishel, Melissa L ^a   Gamcsik, Michael P ^b   Delaney, Shannon M ^a   Zuhowski, Eleanor G ^c   Maher, Veronica M ^d   Karrison, Theodore ^a   Moschel, Robert C ^e   Egorin, Merrill J ^c   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Cisplatin; Modulation

Indexed keywords

BUTHIONINE SULFOXIMINE; CISPLATIN; DNA; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GUANINE DERIVATIVE; O 6 BENZYLGUANINE; PLATINUM; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL LEVEL; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; EXCISION REPAIR; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL SURVIVAL; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG SYNERGISM; GLUTATHIONE; GUANINE; HUMANS; PLATINUM; TUMOR CELLS, CULTURED;

EID: 15044344097     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0901-3     Document Type: Article

References (50)

1. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56(13):3087-3090
2. Barret JM, Cadou M, Hill BT (2002) Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F11782, a novel fluorinated epipodophylloid. Biochem Pharmacol 63:251-258
3. Bible KC, Kaufmann SH (1997) Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 57(16):3375-3380
4. Bohr VA, Smith CA, Okumoto DS, Hanawalt PC (1985) DNA repair in an active gene: removal of pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than in the genome overall. Cell 40(2):359-369
5. Brabec V, Kasparkova J (2002) Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat 5(3-4):147-161
6. 6-alkylguanine-DNA alkyltransferases. Cancer Res 60(19):5464-5469
7. Chien M, Astumian M, Liebowitz D, Rinker-Schaeffer C, Stadler WM (1999) In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol 44(1):81-87
8. Commandeur JN, Stijntjes GJ, Vermeulen NP (1995) Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role in bioactivation and detoxication mechanisms of xenobiotics. Pharmacol Rev 47(2):271-330
9. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ (2000) Cisplatin resistance and oncogenes - a review. Anticancer Drugs 11(4):225-236
10. 6-benzylguanine and its role in chemotherapy. Clin Cancer Res 3(6):837-847
11. 6- benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 87(14):5368-5372
12. 6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol 16(5):1803-1810
13. Eastman A (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34(2):155-166
14. Einhorn LH (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99(7):4592-4595
15. Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D (1986) Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 4(10):1506-1509
16. Erkmen K, Egorin MJ, Reyno LM, Morgan R Jr, Doroshow JH (1995) Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother Pharmacol 35(3):254-256
17. Ferry KV, Hamilton TC, Johnson SW (2000) Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 60(9):1305-1313
18. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24(3):707-713
19. 6-benzylguanine. Mol Cancer Ther 2:633-640
20. 6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16(11):3570-3575
21. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 18(20):3522-3528
22. Gharehbaghi K, Szekeres T, Yalowitz JA, Fritzer-Szekeres M, Pommier YG, Jayaram HN (2000) Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo. Life Sci 68:1-11
23. Giaccone G (2000) Clinical perspectives on platinum resistance. Drugs 59 [Suppl 4]:9-17; (discussion 37-38)
24. Gibson AE, Arris CE, Bentley J, Boyle FT, Curtin NJ, Davies TG, Endicott JA, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble ME, Tucker JA, Whitfield HJ (2002) Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem 45(16):3381-3393
25. Griffith OW (1982) Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of alutathione synthesis. J Biol Chem 257(22):13704-13712
26. Habig WH, Jakoby WB (1981) Assays for differentiation of glutathione S-transferases. Methods Enzymol 77:398-405
27. Habig WH, Pabst MJ, Jakoby WB (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249(22):7130-7139
28. Hagrman D, Goodisman J, Souid AK (2004) Kinetic study on the reactions of platinum drugs with glutathione. J Pharmacol Exp Ther 308(2):658-666
29. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF (1985) Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34(14):2583-2586
30. Hartmann JT, Lipp HP (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4(6):889-901
31. Hromas RA, Andrews PA, Murphy MP, Burns CP (1987) Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett 34(1):9-13
32. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10(2):257-263
33. Jiang H, Yang LY (1999) Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res 59(18):4529-4534
34. Karran P (2001) Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 22(12):1931-1937
35. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478(1-2):23-43
36. Klungland A, Hoss M, Gunz D, Constantinou A, Clarkson SG, Doetsch PW, Bolton PH, Wood RD, Lindahl T (1999) Base excision repair of oxidative DNA damage activated by XPG protein. Mol Cell 3(1):33-42
37. Lee SK, Yu SL, Prakash L, Prakash S (2002) Requirement of yeast RAD2, a homolog of human XPG gene, for efficient RNA polymerase II transcription: implications for Cockayne syndrome. Cell 109(7):823-834
38. Li QQ, Yunmbam MK, Zhong X, Yu JJ, Mimnaugh EG, Neckers L, Reed E (2001) Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Cell Mol Biol (Noisy-le-grand) 47 Online Pub:OL61-OL72
39. Masters JR, Koberle B (2003) Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer 3(7):517-525
40. Matranga CB, Shapiro GI (2002) Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 62(6):1707-1717
41. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG (1992) Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 52(24):6885-6889
42. Mellon I, Spivak G, Hanawalt PC (1987) Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell 51(2):241-249
43. 6-alkylguanine-DNA alkyltransferase. J Med Chem 35(23):4486-4491
44. Nouspikel T, Lalle P, Leadon SA, Cooper PK, Clarkson SG (1997) A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function. Proc Natl Acad Sci U S A 94(7):3116-3121
45. 6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 6(8):3025-3031
46. Smith SM, Ludeman SM, Wilson LR, Springer JB, Gandhi MC, Dolan ME (2003) Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells. Cancer Chemother Pharmacol 52:291-302
47. 6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 59(10):2402-2410
48. Toogood PL (2001) Cyclin-dependent kinase inhibitors for treating cancer. Med Res Rev 21(6):487-498
49. Yang LY, Li L, Keating MJ, Plunkett W (1995) Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 47(5):1072-1079
50. Zhang K, Chew M, Yang EB, Wong KP, Mack P (2001) Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 59(4):837-843